BMBF funded project "LIL-Invest: Investment project for the strategic expansion of the research infrastructure of Land-Innovation-Lausitz" (FKZ: 03WIR30IL1) BMBF program "Innovation & Structural Change -> WIR! Change through Innovation in the Region"
One research area of the "LIL" land use strategy is the research and marketing of plant ingredients from native and new site-adapted herbs and crops, for which the development and use of analytical and sensory methods for qualitative and quantitative ingredient determination is essential. High-resolution analytical methods allow the determination and enzymatic modification of functional agents and drugs in different biomasses. To address this issue, the expansion of the already established, modern equipment of the FG Enzyme Technology by means of highly sensitive equipment for the detection of ingredients, active ingredients and metabolites in biological samples, catalysis assays and other matrices is funded.
Duration 2021-2022
PERsonalized medicine through FUNCTIONomics in BB: Drug metabolization module for drug testing on patient cells.
PER-FUNCTION BB is an ERDF-funded research network consisting of BTU Cottbus-Senftenberg (Prof. K. Scheibner and Prof. J.-H. Küpper) and University of Potsdam (Prof. F. Jung and PD. Dr. Burkard Schulz). This project is funded by the European Regional Development Fund and the State of Brandenburg.
The innovative research approach announced will potentiate the possibilities of companion diagnostics, i.e. stratification of patients with regard to the response to a therapy, which is mainly carried out on the genome and protein level today! The new technology platform of patient-individualized in vitro drug testing is referred to as "FUNCTIONOMICS" in addition to genomics, metabolomics and proteomics. The essential prerequisite for FUNCTIONOMICS, which is feasible in the presented research concept, is that not only the respective active ingredient is investigated in the administration form on patient cell types, but also that the active metabolites formed in the liver can be tested preparatively for the first time.
Duration: 2016-2020
German Federal Foundation for the Environment ChemBioTec Research Network
"Robust microbial peroxygenases and their applicability in the chemical synthesis of bulk chemicals."
Successful industrial application of enzyme-based biocatalysis requires certain minimum space-time yields and commercial availability of the proteins to be used, sufficient selectivity and stability of the biocatalysts, and knowledge of the optimal reaction conditions.The aim is the environmentally assessed evaluation of the application potential of novel, robust peroxygenases in the chemical synthesis of cyclohexanone and formaldehyde, among others, as model compounds, whose preparative biocatalytic presentation will be comparedwith conventional chemical processes in terms of economic feasibility and environmental relevance.
Duration: 2012-2016
BMBF Research Network BioIndustry 2021, Integrated Bioindustry Cluster
"Functional P450 monooxygenase-peroxidase hybrid enzymes (peroxygenases) for pharmaceutical and bioindustrial synthesis".
Development of a catalysis platform for regio- and stereoselective biosynthesis of basic drug structures, not only biocatalytically substituting conventional syntheses, but also opening up completely new synthesis steps based on fermentative access to non-commercial oxidoreductases.
Duration: 2012-2015
Junior Research Group - "In vitro liver metabolism".
Development of a multi-step biotechnological process for the production of liver first-pass drug metabolites and in vitro analysis of liver-specific metabolic processes.
The junior research group is supported by the Ministry of Labor, Social Affairs, Women and Family with funds from the European Social Fund and the State of Brandenburg.
Duration: 2013-2015
Project EXIST Research Transfer BMWI - Funding Phase I
"Enzymatic synthesis of human liver first-pass drug metabolites."
Interdisciplinary development of processes based on innovative fungal enzymes described for the first time by the applicants and novel systems of physiologically highly active human liver cells for the production of human liver first-pass drug metabolites. In doing so, the goal is to achieve a quantum leap in the production of high-cost drug metabolites for drug discovery and to develop a new generation of liver-tolerant drugs.
Duration: 2011-2013
Project / Coordination of the DBU Research Network
"Development of an innovative production process for the environmentally friendly synthesis of the model compounds (R)-1-phenylethanol and 7-hydroxymethotrexate by using the novel enzyme classes of fungal peroxygenases".
Use of fungal peroxygenases - in environmentally friendly production processes for oxyfunctionalization of specialty chemicals in the pharmaceutical and chemical industries.
Duration: 2008-2010